Strengthening product capabilities, sales capabilities and consultative sales
First written in FY2016. 15 of 28 entries say "Restated". Latest entry: 2026-09-16.
1 other company's latest entry also says "Advanced".
- 2026-09-16AdvancedOther Disclosures
「当委員会で取りまとめたグループ共通方針のもと、グループ各社が連携して施策を推進することで、施策推進の実効性を高め、グループ共通課題への対応力向上につなげます。」
医療用医薬品等卸売事業の基盤強化について、営業戦略に加えて物流・ソリューション・事業運営基盤の最適化をグループ横断で協議・推進する体制へ具体化している。canonical thread は変更しない。 - FY2026ReframedAnnual report
「In the self-medication wholesale business, consolidated subsidiary アルフレッサ ヘルスケア株式会社 is working under the theme “Health × Connecting × Happiness” on the priority initiatives set out in the 25-27 Medium-Term Management Plan: developing a sales strategy resilient to changes in the external environment and developing new solutions led by the company itself.」
The company has reorganised its priorities from initiatives centred on conventional product strength, exclusive products and consultative sales to a sales strategy that increases resilience to the external environment and the development of company-led solutions. - FY2025AdvancedAnnual report
「In March 2025, アルフレッサ ヘルスケア entered into a capital and business alliance agreement with ウィルベース株式会社, which provides healthcare-focused sales-promotion and marketing support and self-medication promotion tools.」
In the self-medication wholesale business, the capital and business alliance with a sales-promotion and marketing support company gave concrete form to data-driven management, including market forecasting, new-product planning and sales-promotion optimisation. - FY2024AdvancedAnnual report
「In February 2024, the company held the 2024 Life Support Fair exhibition at the Hamamatsucho Building of the Tokyo Metropolitan Industrial Trade Center in Minato-ku, Tokyo. Under the theme “New Gate—Creating the Drugstores of a New Era,” it proposed store merchandising that anticipated change while preserving what should not change, with the changing social environment in mind.」
In the self-medication wholesale business, the company proposed store merchandising for drugstores in a new era through an exhibition. - FY2024-Q2AdvancedAnnual report
「In the self-medication wholesale business, we are promoting efforts to improve profitability in existing areas and pursue growth areas, as well as the initiatives identified as priorities under the 22-24 Medium-Term Management Plan: improving profitability, strengthening group coordination and enhancing earnings power through business transformation. In particular, we have worked to address higher procurement costs resulting from inflation and create new channels, including by developing sales channels to dispensing pharmacies.」
In the self-medication wholesale business, the company gave concrete form to its efforts to improve profitability in existing areas and pursue growth areas by addressing higher procurement costs and developing sales channels to dispensing pharmacies. - FY2023-Q2ReframedAnnual report
「In the self-medication wholesale business, we are promoting the generation of higher profitability in existing businesses and pursuing growth areas, while implementing the priority measures identified under the “22-24 Medium-Term Management Plan”: “Initiatives to improve profitability,” “Strengthening group collaboration,” and “Strengthening earnings capacity through business transformation.”」
The company is refocusing its priorities from initiatives centred on conventional product proposals and exclusive products to improving profitability in existing areas, pursuing growth areas, strengthening group coordination and enhancing earnings power through business transformation. - FY2022-Q3RestatedAnnual report
「In the self-medication wholesale business, we continue to promote the “Total Healthcare Merchandising Wholesaler” concept and pursue a unique wholesale business differentiated by new added value and creativity, while continuing to implement the priority measures identified under the “19-21 Medium-Term Management Plan,” including “Establishing a stable and sustainable business platform,” “Product proposals from the consumer’s perspective,” and “Strengthening initiatives involving exclusive manufacturers and products.”」
The company continues to strengthen the self-medication wholesale business through consumer-focused product proposals, exclusive products and a stable business foundation. - FY2022-Q2RestatedAnnual report
「In the self-medication wholesale business, we continue to promote the “Total Healthcare Merchandising Wholesaler” concept and pursue a unique wholesale business differentiated by new added value and creativity, while continuing to implement the priority measures identified under the “19-21 Medium-Term Management Plan,” including “Establishing a stable and sustainable business platform,” “Product proposals from the consumer’s perspective,” and “Strengthening initiatives involving exclusive manufacturers and products.”」
The company continues initiatives involving its unique total-healthcare wholesale function, business foundations, product proposals and exclusive products. - FY2022-Q1RestatedAnnual report
「In the self-medication wholesale business, we continue to promote the “Total Healthcare Merchandising Wholesaler” concept and pursue a unique wholesale business differentiated by new added value and creativity, while continuing to implement the priority measures identified under the “19-21 Medium-Term Management Plan,” including “Establishing a stable and sustainable business platform,” “Product proposals from the consumer’s perspective,” and “Strengthening initiatives involving exclusive manufacturers and products.”」
The company continues key initiatives in the self-medication wholesale business, including product proposals, exclusive products and business-foundation strengthening. - FY2021-Q3RestatedAnnual report
「In the self-medication wholesale business, we continue to promote the “Total Healthcare Merchandising Wholesaler” concept and pursue a unique wholesale business differentiated by new added value and creativity, while continuing to implement the initiatives identified as priority measures under the “19-21 Medium-Term Management Plan”: “Establishing a stable and sustainable business platform,” “Product proposals from the consumer’s perspective,” “Strengthening initiatives involving exclusive manufacturers and products,” “Investing for the future,” and “Strengthening collaboration with each business segment.”」
The company continues to strengthen its sales and business foundations through consumer-focused product proposals, exclusive products, investment and segment coordination. - FY2021-Q2RestatedAnnual report
「We continue to work on establishing a stable and sustainable business foundation, proposing products from the consumer’s perspective, strengthening initiatives involving exclusive manufacturers and products, investing for the future, and strengthening coordination with each business segment.」
The company continues initiatives involving product proposals, exclusive products, investment and segment coordination in the self-medication wholesale business. - FY2021-Q1AdvancedAnnual report
「For the segment's first-quarter cumulative consolidated period, net sales were ¥6.4656 billion, down 3.1% year on year, while operating income was ¥688 million, up 77.8%, despite a sharp decline in inbound demand caused by the spread of COVID-19, owing to increased sales of infection-prevention products and more thorough cost management.」
Although revenue declined due to lower inbound demand, operating profit in the self-medication wholesaling business increased 77.8% year on year, owing to higher sales of infection-prevention-related products and cost management. - FY2020-Q3RestatedAnnual report
「In the self-medication wholesale business, the company is promoting the concept of a total healthcare merchandising wholesaler and aiming to become a one-of-a-kind wholesaler differentiated and creative through new added value. As key initiatives under the 19-21 medium-term management plan, it is pursuing the establishment of a stable and sustainable business foundation, consumer-oriented product proposals, stronger initiatives involving exclusive manufacturers and products, investment for the future, and stronger collaboration among business segments.」
The company continues to pursue a total-healthcare wholesaling function, differentiation as the only wholesaler of its kind, and five key measures in the self-medication wholesaling business. - FY2020-Q2RestatedAnnual report
「In the self-medication wholesale business, the company is promoting the concept of a total healthcare merchandising wholesaler and aiming to become a one-of-a-kind wholesaler differentiated and creative through new added value. As key initiatives under the 19-21 medium-term management plan, it is pursuing the establishment of a stable and sustainable business foundation, consumer-oriented product proposals, stronger initiatives involving exclusive manufacturers and products, investment for the future, and stronger collaboration among business segments.」
The company continues to pursue its policy of becoming the only wholesaler of its kind and its five key measures. - FY2020-Q1RestatedAnnual report
「In the self-medication wholesale business, the company is promoting the concept of a total healthcare merchandising wholesaler and aiming to become a one-of-a-kind wholesaler differentiated and creative through new added value. As key initiatives under the 19-21 medium-term management plan, it is pursuing the establishment of a stable and sustainable business foundation, consumer-oriented product proposals, stronger initiatives involving exclusive manufacturers and products, investment for the future, and stronger collaboration among business segments.」
In the self-medication wholesaling business, the company continues to pursue initiatives involving its business foundation, consumer-oriented product proposals, exclusive products, investment and segment collaboration. - FY2019RestatedAnnual report
「In the self-medication wholesaling business, the company continued to pursue the “further strengthening of the business foundation” and “strengthening value-added sales” identified as key measures under the “16-18 medium-term management plan.”」
The company continued to strengthen its business foundation and value-added sales, resulting in higher revenue and higher profit through stronger sales of exclusive products and products from exclusive manufacturers, among other measures. - FY2019-Q3AdvancedAnnual report
「Alfresa Healthcare Co., Ltd., a consolidated subsidiary of the company (headquartered in Chuo-ku, Tokyo), opened a representative office in Taipei in November 2018 to support the promotional activities of its customers operating retail stores in Taiwan and to promote sales of its exclusive products and products from exclusive manufacturers.」
The company opened a representative office in Taiwan to support the promotion of exclusive products and products from exclusive manufacturers, implementing concrete measures to strengthen sales capabilities. - FY2019-Q2RestatedAnnual report
「In the self-medication wholesale business, the company continues to pursue the initiatives identified as key measures under the 16-18 medium-term management plan, namely further strengthening the business foundation and strengthening value-added sales.」
The company continues to strengthen its business foundation and value-added sales. While the segment reported higher revenue, operating profit decreased 2.9% year on year. - FY2019-Q1RestatedAnnual report
「As a result of working to secure stable sales and profits by expanding sales of high-margin exclusive products, the segment reported net sales of ¥68,076 million, up 2.6% year on year, and operating profit of ¥682 million, up 4.5%, for the cumulative consolidated first quarter.」
The company continued to expand sales of high-margin exclusive products, and the self-medication wholesaling business reported higher revenue and higher profit. - FY2018-Q3RestatedAnnual report
「In the self-medication wholesaling business, the company continued to pursue the “further strengthening of the business foundation” and “strengthening value-added sales” identified as key measures for the segment under the 16-18 medium-term management plan. It worked to secure stable profits by reducing costs through logistics reform promoted across the company, holding solution-oriented business meetings to propose new value to customers, and expanding its range of high-margin exclusive products.」
The company continues to implement business foundation enhancement, value-added sales, logistics reform, solution-oriented business meetings and expansion of exclusive products. - FY2018-Q2RestatedAnnual report
「The company continued to pursue the “further strengthening of the business foundation” and “strengthening value-added sales” identified as key measures for each segment under the 16-18 medium-term management plan. It worked to secure stable profits by reducing costs through logistics reform promoted across the company, holding solution-oriented business meetings to propose new value to customers, and expanding its range of high-margin exclusive products.」
The company continues to implement business foundation enhancement, value-added sales, logistics reform, solution-oriented business meetings and expansion of exclusive products. - FY2018-Q1RestatedAnnual report
「The company continued to pursue the “further strengthening of the business foundation” and “strengthening value-added sales” identified as key measures for each segment under the 16-18 medium-term management plan. It worked to secure stable profits by reducing costs through logistics reform promoted across the company, holding solution-oriented business meetings to propose new value to customers, and expanding its range of high-margin exclusive products.」
The company continues to implement business foundation enhancement, value-added sales, logistics reform, solution-oriented business meetings and expansion of exclusive products. - FY2017-Q3AdvancedAnnual report
「In the self-medication wholesale business, the company worked to secure stable profits by holding solution-oriented business meetings proposing new added value to customers, focusing on sales of high-margin exclusive products, and reducing costs through the logistics reform being pursued across the company.」
The company continued solution-oriented business meetings, sales of exclusive products and logistics reform, and operating profit in the business increased 88.5% year on year. - FY2017-Q2AdvancedAnnual report
「In the self-medication wholesale business, the company worked to secure stable profits by holding solution-oriented business meetings proposing new added value to customers, focusing on sales of high-margin exclusive products, and reducing costs through the logistics reform being pursued across the company.」
In addition to the existing initiatives of selling exclusive products and logistics reform, the company held solution-oriented business meetings. Segment operating profit also increased 58.6% year on year, indicating execution of the initiatives and measurable progress. - FY2017-Q1RestatedAnnual report
「In the self-medication wholesale business, the company worked to secure stable profits by focusing on cost reductions from the logistics reform being pursued across the company and sales of high-margin exclusive products.」
The company continues its existing initiatives of reducing costs through logistics reform and selling exclusive products. - FY2016First statedAnnual report
「The company will differentiate itself from competitors and build a strong business foundation by strengthening its product and sales capabilities. It will expand exclusive products, including high-quality, high-value-added health foods and foods with health claims, thoroughly implement high-value-added consultative sales, and improve customer satisfaction.」
The measures are intended to differentiate the self-medication wholesaling business through expanding exclusive products and consultative sales.